← Back to Search

LY03003 for Parkinson's Disease

Phase 1
Waitlist Available
Led By Ahad Sabet, MD
Research Sponsored by Luye Pharma Group Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Approved for 5 Other Conditions
No Placebo-Only Group
All Individual Drugs Already Approved

Summary

This is a randomized, open-label, 2-sequence, 2-treatment cross-over study in healthy adult subjects. Rotigotine PK profiles will be obtained from all subjects after both a single dose of 28 mg LY03003 and 1 week of 4 mg q24h NEUPRO® patch. Subjects will be randomized 1:1 to 1 of the 2 treatment sequences.

Eligible Conditions
  • Parkinson's Disease
  • Overactive Bladder

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: LY03003Experimental Treatment1 Intervention
LY03003 28 mg
Group II: Neupro 4Mg/24Hr Transdermal PatchActive Control1 Intervention
Neupro 4 mg / 24 Hr. Transdermal Patch
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Rotigotine
FDA approved

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Luye Pharma Group Ltd.Lead Sponsor
64 Previous Clinical Trials
9,707 Total Patients Enrolled
Ahad Sabet, MDPrincipal InvestigatorPharmaceutical Research Associates
3 Previous Clinical Trials
125 Total Patients Enrolled
~10 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top